BusinessAdaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple MyelomaBy Nasdaq OMXOct 27, 2016, 2:05 PM UTC
BusinessRadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)By Nasdaq OMXOct 20, 2016, 6:30 AM UTC
BusinessNovan to Present Data from SB204 Phase 2b Trial at Fall Clinical Dermatology ConferenceBy Nasdaq OMXOct 18, 2016, 1:05 PM UTC
BusinessAdaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian CancerBy Nasdaq OMXOct 12, 2016, 1:15 PM UTC
BusinessClearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) MeetingBy Nasdaq OMXOct 10, 2016, 11:00 AM UTC
BusinessAchillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCVBy Nasdaq OMXSep 23, 2016, 3:50 PM UTC
BusinessDr. Mark Schiller to present PEER at American College of Private PhysiciansBy Nasdaq OMXSep 22, 2016, 9:00 AM UTC
